# Reclassifying cannabis? Implications for recreational/medical marijuana use, research, drug policy Source: https://www.youtube.com/watch?v=RnjOalf8vgA Recap page: https://rapidrecap.app/video/RnjOalf8vgA Generated: 2026-02-24T20:03:35.495+00:00 --- ## Quick Overview President Trump signed an executive order to expedite the rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act, a move that experts agree is extremely close to finalization despite procedural holdups, with the immediate guaranteed benefit being the elimination of the restrictive tax code Section 280E for state-licensed cannabis businesses. **Key Points:** - The federal rescheduling process was accelerated by President Trump's executive order, building on a 2022 rescheduling petition initiated by President Biden, moving cannabis from Schedule I to Schedule III. - Vanderbilt Law Professor Rob Mikos states that the only guaranteed benefit of rescheduling to Schedule III is the elimination of Section 280E, which currently prevents cannabis companies from claiming ordinary tax deductions. - Dr. Peter Ginspoon, a primary care doctor, argues that rescheduling constitutes less stigma, better research, and is an admission by the US government that cannabis is a medicine, noting that tobacco kills 500,000 people annually while cannabis is scheduled higher. - Ephetio Taio Harvey of the People of Color Psychedelic Collective asserts that rescheduling to Schedule III is "a dollar short and a day late" and does not address the racialized harms of cannabis prohibition, advocating instead for full federal decriminalization or descheduling. - Hersh Jane, an industry advisor, notes that rescheduling will catalyze long-term changes in banking access, state-level reform, federal policy, and the international landscape, even if these changes are not immediate. - Rob Mikos clarifies that rescheduling does not automatically legalize sales, as Schedule III drugs still require DEA licensing, and selling marijuana still violates the Food Drug and Cosmetic Act because HHS emphatically stated it is not approving marijuana as a drug. - Dr. Ginspoon hopes rescheduling will decrease stigma, lower prices by eliminating 280E costs, and improve research by allowing scientists to study the actual cannabis products patients use, rather than only government-supplied samples. **Context:** This webinar, hosted by the Petri Flom Center at Harvard Law School and moderated by Dr. Mason Marks, convened experts from medicine, industry, advocacy, and law to analyze the implications of the federal rescheduling of cannabis from Schedule I to Schedule III, an action expedited by an executive order signed by President Trump in late 2025. The discussion covered the legal criteria for rescheduling, the historical context of cannabis prohibition dating back to 1970, and the potential economic, clinical, and social justice consequences of this significant regulatory shift. ## Detailed Analysis The federal rescheduling of cannabis from Schedule I to Schedule III is underway, following Attorney General Merrick Garland's 2024 proposal, which reinterpreted the statutory criteria for 'currently accepted medical use' to include state medical legalization and physician recommendations, rather than strictly FDA approval. While the final rule is pending procedural finality, experts believe the odds of completion are extraordinarily high, potentially requiring only a decision from the current Attorney General Pam Bondi to bypass further hearings. The most immediate economic impact is the elimination of Section 280E, which will make state-licensed cannabis businesses more profitable, though experts debate whether these savings will flow to consumers, workers, or company profits. However, rescheduling does not equate to full federal legalization; Schedule III status still requires DEA licensing for handling, and the sale of marijuana continues to violate the Food Drug and Cosmetic Act since HHS is not approving it as an FDA-approved drug, suggesting banking and trademark access may not improve overnight. Clinically, rescheduling may decrease patient stigma, potentially lower prices that currently deter access for low-income users, and lead to better research using relevant cannabis products. Advocates like Ephetio Taio Harvey criticize the rescheduling as insufficient, demanding full decriminalization or descheduling to address the legacy of racially disparate enforcement of the War on Drugs, noting that rescheduling does nothing to remedy past convictions or destroyed lives. Furthermore, rescheduling is viewed as a 'half measure' that distracts from broader drug policy reform, although experts suggest increased legalization in 'red states' and examining international models like Canada's success might build momentum for more progressive federal action. ### Rescheduling Status and Legal Hurdles - President Trump expedited rescheduling from Schedule I to Schedule III based on AG Garland's finding that cannabis has 'currently accepted medical use' based on state laws and physician recommendations - The final step requires a final rule from the Attorney General, which is expected soon despite procedural disputes over hearings. ### Economic Implications for Industry - Rescheduling immediately eliminates tax code Section 280E for licensed businesses, which previously prevented ordinary business expense deductions - Hersh Jane suggests monitoring where 280E savings flow, potentially lowering prices or improving wages, while Rob Mikos confirms 280E applies only to Schedule I and II drugs. ### Clinical and Patient Benefits - Dr. Peter Ginspoon anticipates decreased stigma, lower prices for patients who currently struggle to afford medical cannabis over insurance-covered alternatives, and improved research quality - He notes that rescheduling validates cannabis as medicine, which aids open conversations between doctors and patients. ### Limitations of Schedule III Status - Rescheduling does not legalize sales; handling Schedule III drugs like Ketamine requires a DEA license - HHS explicitly stated it is not approving marijuana as a drug, meaning sales still violate the Food Drug and Cosmetic Act, potentially hindering banking and trademarking. ### Advocacy and Social Justice Critique - Ephetio Taio Harvey argues rescheduling is 'a dollar short and a day late,' failing to address the devastating racial disparities and criminal records resulting from cannabis prohibition - She advocates for full federal decriminalization or descheduling, citing the historical targeting of Black and Latino communities. ### Future Policy Trajectory - Experts suggest that increased legalization in Republican-controlled states and examining international examples like Canada will be necessary to build momentum for broader federal criminal justice reform and decriminalization - Dr. Ginspoon warned against underestimating the power of prohibitionist industry groups actively seeking to recriminalize cannabis via ballot initiatives.